Plasminogen activator inhibitor-1 as a potential marker for the malignancy of gastric cancer
Plasminogen activator inhibitor-1 as a potential marker for the malignancy of gastric cancer
复制标题
DOI：
10.1111/j.1349-7006.2006.00185.x
复制
发表时间：
2006-05-01
期刊：
影响因子：
5.7
通讯作者：
Nakao, A
中科院分区：
文献类型：
--
作者：
Sakakibara, T;Hibi, K;Nakao, A
为了验证纤溶酶原激活物抑制剂-1 （PAI-1）可能作为胃癌恶性肿瘤的候选标志物的假设，我们对PAI-1基因进行了定量逆转录-聚合酶链反应，并评估PAI-1基因表达水平与胃癌临床病理表现的可能关系。PAI-1表达评分在淋巴结转移阳性胃癌（2.11 +/- 0.35）与转移阴性胃癌（0.33 +/- 0.49）相比显著升高（P = 0.0048），在远处转移阳性胃癌（3.68 +/- 0.58）与转移阴性胃癌（1.20 +/- 0.32）相比显著升高。PAI-1表达评分随肿瘤分期明显升高（P < 0.0001；方差分析）。此外，多因素分析显示PAI-1表达评分是胃癌预后的重要独立因素（P = 0.0450）。这些结果提示PAI-1可能作为预测胃癌预后的一个新的、有前景的参数。
To test the hypothesis that plasminogen activator inhibitor-1 (PAI-1) may serve as a candidate marker for the malignancy of gastric cancer, we carried out quantitative reverse transcription-polymerase chain reaction for the PAI-1 gene and evaluated the possible relationship between PAI-1 gene expression levels and clinicopathological findings in gastric cancer. A significant increase in PAI-1 expression scores was observed in lymph node metastasis-positive gastric cancers (2.11 +/- 0.35) compared to metastasis-negative cancers (0.33 +/- 0.49) (P = 0.0048), as well as in distant metastasis-positive gastric cancers (3.68 +/- 0.58) compared to metastasis-negative cancers (1.20 +/- 0.32). The PAI-1 expression score markedly increased with tumor stage (P < 0.0001; ANOVA test). Moreover, multivariate analysis revealed the PAI-1 expression score to be a strong and independent prognostic factor for gastric cancer (P = 0.0450). These results suggested that PAI-1 might serve as a new and promising parameter for the prediction of prognosis in gastric cancer.